Biotechnology has contributed to important advances in the healthcare field. Products include various hormones, enzymes, cytokines, vaccines, and monoclonal antibodies, with use in diverse therapeutic areas. The majority of approved biotechnology-derived therapeutic products are recombinant proteins. Many have orphan drug status and, therefore, are used in relatively small patient populations. Newer generation biotechnology products are likely to include small molecules, gene therapy products, and increased numbers of vaccines and monoclonal antibody products. Biotechnology provides the means to develop diverse, innovative, and effective approaches to the prevention, treatment, and cure of human disease.
Get full access to this article
View all access options for this article.
References
1.
Biotechnology Medicines in Development.. Washington, D.C: Pharmaceutical Research and Manufacturers of America; 1996:
Hillman Rs.Hematopoietic agents: Growth factors, minerals, and vitamins, Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th Ed.Hardman JgLimbird LeMolinoff PbRuddon RwGilman Ag, ed. New York, NY: McGraw-Hill; 1996:1311-1340.
4.
Eschbach Jw,Abdulhadi Mh,Browne Jk.“Recombinant human erythropoietin in anemic patients with end-stage renal disease,”.Ann. Int. Med.. 1989;111:992-1000
5.
“Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients,”.Am. J. Kid. Dis.. 1991;18:50-59
6.
Fischl M,Galpin Je,Levine Jd.“Recombinant human erythropoietin for patients with aids treated with zidovudine,”.N. Eng. J. Med.. 1990;322:1488-1493
7.
Abels Ri.“Recombinant human erythropoietin in the treatment of the anaemia of cancer,”.Acta Haematologica. 1992;87 (Suppl. 1): 4-11
8.
Deandrade Jr,Jove M,Landon G.“Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin alfa in orthopedic surgery patients,”.Am. J. Orthop.. 1996;25:533-542
9.
Crawford J,Ozer H,Stoller R.“Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer,”.N. Eng. J. Med.. 1991;325:164-170
10.
Schmitz N,Linch Dc,Dreger P.“Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients,”.Lancet. 1996;347:353-357
11.
Dale Dc,Bonilla Ma,Davis Mw.“A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (Filgrastim) for treatment of severe chronic neutropenia,”.Blood. 1993;81:2496-2502
12.
Nemunaitis J,Rabinowe Sn,Singer Jw.“Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer,”.N. Eng. J. Med.. 1991;324:1773-1778
13.
Rowe Jm,Andersen Jw,Mazza Jj.“A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (55 to 70 years of age) with acute myelogenous leukemia: a study of the eastern cooperative oncology group (E1490),”.Blood. 1995;86:457-162
14.
Hayden Fg.Antimicrobial agents: antiviral agents, Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th EdHard-Man JgLimbird LeMolinoff PbRuddon RwGilman Ag, ed. New York, NY: McGraw-Hill; 1996:1211-1214.
15.
Borden Ec..“Interferons-expanding therapeutic roles,”.N. Eng. J. Med.. 1992;326:1491-1493
16.
Interferon alfa-n3.. St. Louis, MO: Facts Comparisons; 1997:
17.
Ratain Mj,Vardiman Jw,Golomb Hm..“The role of interferon in the treatment of hairy cell leukemia,”.Sem. Oncol.. 1986;13 (suppl. 2): 21-28
18.
Talpaz M.“Use of interferon in the treatment of chronic myelogenous leukemia,”.Sem. Oncol.. 1994;21 (suppl. 14): 3-7
19.
Woo Mh,Burnakis Tg.“Interferon alfa in the treatment of chronic viral hepatitis B and C,”.Ann. Pharmacother.. 1997;31:330-337
20.
Tong Mj,Reddy Kr,Lee Wm.“Treatment of chronic hepititis C with consensus interferon: a multicenter, randomized, controlled trial,”.Hepatology. 1997;26:747-754
Sechler Jmg,Malech Hl,White Cj.“Recombinant human interferon-gamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood,”.Proc. Natl. Acad. Sci.. 1988;85:4874-4878
28.
Ezekowitz Rab,Dinauer M.C.,Jaffe Hs.“Partial correction of the phagocyte defect in patients with x-linked chronic granulomatous disease by subcutaneous interferon gamma,”.N. Eng.J. Med.. 1988;319:146-151
29.
“A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease,”.N. Eng. J. Med.. 1991;324:509-516
30.
Gordon Ms,Schucter Lm.Hematology: Basic Principles and Practice. 2nd EditionHoffman RBenz EjShattil SjFurie BCohen HjSilberstein Le, ed. New York, NY: Churchill Livingstone Inc.; 1995:955-981.
31.
Taneja Ss,Pierce W,Figlin R.“Immuno-therapy for renal cell carcinoma: the era of interleukin-2-based treatment,”.Urol.. 1995;45:911-924
32.
Fyfe G,Fisher Ri,Rosenberg Sa.“Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose re-combinant interleukin-2 therapy,”.J. Clin. On-col.. 1995;13:688-696
33.
Shak S,Capon Dj,Hellmiss R.“Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum,”.Proc. Natl. Acad. Sci.. 1990;87:9188-9192
34.
Dornase Alfa.. St. Louis, MO: Facts Comparisons; 1997:
35.
Fuchs Hj,Borowitz Ds,Christiansen Dh.“Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis,”.N. Eng. J. Med.. 1994;331:637-642
36.
McCoy K.“Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease,”.Chest. 1996;110:889-895
37.
Menzin J,Oster G,Davies L.“A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis,”.Int. J. Tech. Assess, in Health Care. 1996;12:52-61
38.
McGovern Mm,Desnick RjCecil Textbook of Medicine. 20th EditionBennett JcPlum F, ed. Philadelphia PA: WB Saunders Company; 1996:1095-1099.
39.
Imiglucerase. St. Louis, MO: Facts Comparisons; 1997:
40.
Barton Nw,Brady Ro,Dambrosia Jm.“Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease,”.N. Eng. J. Med.. 1991;324:1464-1470
41.
Grabowski Ga,Barton Nw,Pastures G.“Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources,”.Ann. Int. Med.. 1995;122:33-39
42.
Rosenthal Di,Doppelt Sh,Mankin Hj.“Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase,”.Pediatrics. 1995;96:629-637
44.The National Hemophilia Foundation. What you should know about hemophilia. New York, NY, 1991.
45.
National Hemophilia Foundation Community Alert. 1996;3:1-7
46.
Guerci Ad,Gerstenblith G,Brinker Ja.“A randomized trial of intravenous tissue plas-minogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty,”.N. Eng. J. Med.. 1987;317:1613-1618
47.
Wilcox Rg,Olsson Cg,Skene Am.“Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian study of early thrombolysis (ASSET),”.Lancet. 1988;2:525-530
48.
“An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction,”.N. Eng. J. Med.. 1993;329:673-682
49.
“Tissue plasminogen activator for acute ischemic stroke,”.N. Eng. J. Med.. 1995;333:1581-1587
50.
Noble S,McTavish D..“Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction,”.Drugs. 1996;52:589-605
51.
“Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence,”.Lancet. 1995;346:329-336
52.
Smalling Rw,Bode C,Kalbfleisch J.“More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction,”.Circulation. 1995;91:2725-2732
53.
Bode C,Smalling Rw,Berg G.“Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction,”.Circulation. 1996;94:891-898
Genetta Tb,Mauro Vf.“Abciximab: a new antiaggregant used in angioplasty,”.Ann. Pharmacother.. 1996;30:251-257
56.
“Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty,”.N. Eng. J. Med.. 1994;330:956-961
57.
Topol Ej,Califf Rm,Weisman Hf.“Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months,”.Lancet. 1994;343:881-886
58.
“The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus,”.N. Eng. J. Med.. 1993;329:977-986
59.
Insulin.. St. Louis, MO: Facts Comparisons; 1997:
60.
Brown P,Gajdusek C,Gibbs Cj.“Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy,”.N. Eng. J. Med.. 1985;313:728-731
61.
Human growth hormone.. St. Louis, MO: Facts Comparisons; 1997:
62.
“A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants,”.N. Eng. J. Med.. 1985;313:337-342
